{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:01:45Z","timestamp":1791219705598,"version":"4.1.0"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2019,11,1]]},"DOI":"10.1001\/jamacardio.2019.3355","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T22:25:03Z","timestamp":1569536703000},"page":"1092","source":"Crossref","is-referenced-by-count":137,"title":["Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes"],"prefix":"10.1001","volume":"4","author":[{"given":"Mariusz","family":"Tomaniak","sequence":"first","affiliation":[{"name":"Department of Cardiology, Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands"},{"name":"First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ply","family":"Chichareon","sequence":"additional","affiliation":[{"name":"Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands"},{"name":"Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Onuma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands"},{"name":"Cardialysis Core Laboratories and Clinical Trial Management, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthymios N.","family":"Deliargyris","sequence":"additional","affiliation":[{"name":"PLx Pharma Inc, Sparta, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniaki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Kogame","sequence":"additional","affiliation":[{"name":"Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Modolo","sequence":"additional","affiliation":[{"name":"Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands"},{"name":"Department of Internal Medicine, Cardiology Division, University of Campinas, Campinas, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun Ching","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Rademaker-Havinga","sequence":"additional","affiliation":[{"name":"Cardialysis Core Laboratories and Clinical Trial Management, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[{"name":"Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Dangas","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital Heart and Vascular Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Florida, College of Medicine, Jacksonville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hamm","sequence":"additional","affiliation":[{"name":"University of Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"French Alliance for Cardiovascular Trials, Universit\u00e9 Paris Diderot, H\u00f4pital Bichat, Assistance Publique H\u00f4pitaux de Paris, and INSERM U-1148, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Vranckx","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, Hasselt, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Serruys","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the GLOBAL LEADERS Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"hoi190058r1","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes.","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"9711","key":"hoi190058r2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","article-title":"Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.","volume":"375","author":"Cannon","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"hoi190058r3","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"issue":"8","key":"hoi190058r4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41569-018-0049-1","article-title":"Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention.","volume":"15","author":"Capodanno","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"10151","key":"hoi190058r5","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"hoi190058r6","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.4244\/EIJY15M11_07","article-title":"Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.","volume":"12","author":"Vranckx","year":"2016","journal-title":"EuroIntervention"},{"issue":"24","key":"hoi190058r7","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized end point definitions for coronary intervention trials: the academic research consortium-2 consensus document.","volume":"137","author":"Garcia-Garcia","year":"2018","journal-title":"Circulation"},{"key":"hoi190058r8","doi-asserted-by":"crossref","DOI":"10.4244\/EIJ-D-19-00202","article-title":"Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: Insights from the randomized GLOBAL LEADERS trial.","author":"Serruys","year":"2019","journal-title":"EuroIntervention"},{"issue":"17","key":"hoi190058r9","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","article-title":"Efficacy and safety of dual antiplatelet therapy after complex PCI.","volume":"68","author":"Giustino","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"hoi190058r10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization.","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"issue":"1","key":"hoi190058r11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12265-013-9524-6","article-title":"Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes.","volume":"7","author":"Thomas","year":"2014","journal-title":"J Cardiovasc Transl Res"},{"issue":"8","key":"hoi190058r12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3109\/09537104.2012.748185","article-title":"Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers.","volume":"24","author":"Teng","year":"2013","journal-title":"Platelets"},{"issue":"4","key":"hoi190058r13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1160\/TH13-05-0400","article-title":"Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation.","volume":"110","author":"Tello-Montoliu","year":"2013","journal-title":"Thromb Haemost"},{"issue":"21","key":"hoi190058r14","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/hrt.2010.205724","article-title":"Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?","volume":"96","author":"Warner","year":"2010","journal-title":"Heart"},{"issue":"2","key":"hoi190058r15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/1074248411410883","article-title":"Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model.","volume":"17","author":"van Giezen","year":"2012","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"4","key":"hoi190058r16","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1046\/j.1365-2141.2000.02208.x","article-title":"The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity.","volume":"110","author":"Storey","year":"2000","journal-title":"Br J Haematol"},{"issue":"9748","key":"hoi190058r17","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"issue":"9038","key":"hoi190058r18","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).","volume":"348","author":"Committee","year":"1996","journal-title":"Lancet"},{"key":"hoi190058r19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ahj.2016.09.006","article-title":"Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: rationale and design of the TWILIGHT study.","volume":"182","author":"Baber","year":"2016","journal-title":"Am Heart J"},{"issue":"2","key":"hoi190058r20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/09537104.2019.1572880","article-title":"Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome.","volume":"30","author":"Parker","year":"2019","journal-title":"Platelets"},{"issue":"6","key":"hoi190058r21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jacc.2016.11.050","article-title":"Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus.","volume":"69","author":"Bhatt","year":"2017","journal-title":"J Am Coll Cardiol"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2752077\/jamacardiology_tomaniak_2019_oi_190058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T08:40:34Z","timestamp":1611391234000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2752077"}},"subtitle":["A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial"],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2019.3355","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,1]]}}}